# Nektar Therapeutics (NKTR) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $74.19, market value $2.5 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Nektar Therapeutics reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 46.4×**. Each dollar of revenue is priced at 46.4×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 2.8×**. The shares trade at 2.8× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -9.2%** (5-yr avg -78.8%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -257.8%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -297.1%**. The company reported a net loss over the last twelve months.
- **Return on equity: -182.6%**. Return on equity is negative because earnings are negative.
- **Return on assets: -56.0%**. Each dollar of assets produces -56.0% of profit.

## Growth
- **Revenue growth (1 yr): -43.9%** (3-yr -15.7%/yr, 5-yr -18.4%/yr). Revenue fell 43.9% over the last year, against -18.4% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): -12.1%**. Earnings per share fell 12.1%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Current ratio: 4.97** (quick 4.97). Current assets cover the next year's liabilities 4.97 times.
- **Altman Z-score: 7.88**. A Z-score of 7.88 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Nektar Therapeutics does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (10 analysts). 10 analysts cover Nektar Therapeutics; the consensus is strong_buy, with an average price target of $144.40 (+95% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 106.2%** (YTD 75.5%, 3-mo 29.4%). The shares are up 106.2% over twelve months including dividends.
- **From 52-week high: -31.9%** (122.1% above the low). Trading 32% below its 52-week high, deep in a drawdown.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 53**. An RSI of 53 is neutral.
- **Beta (1 yr): 1.30** (volatility 85%). Beta of 1.30 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=NKTR · Page: https://foliofundamentals.com/stocks/nktr

Not investment advice.